Forte Biosciences (FBRX) EBIT Growth (5y) (2021 - 2026)
Forte Biosciences (FBRX) EBIT Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.47% |
| Dec 31, 2025 | -40.47% |
| Sep 30, 2025 | -29.70% |
| Jun 30, 2025 | 19.73% |
| Mar 31, 2025 | -51.40% |
| Dec 31, 2024 | -36.28% |
| Sep 30, 2024 | -66.03% |
| Jun 30, 2024 | -82.74% |
| Mar 31, 2024 | 14.29% |
| Dec 31, 2023 | 19.70% |
| Sep 30, 2023 | -55.73% |
| Jun 30, 2023 | 10.03% |
| Mar 31, 2023 | 11.80% |
| Dec 31, 2022 | 14.30% |
| Sep 30, 2022 | 18.87% |
| Jun 30, 2022 | 18.98% |
| Mar 31, 2022 | 21.72% |
| Dec 31, 2021 | 16.18% |
| Sep 30, 2021 | 2.03% |
| Jun 30, 2021 | 5.49% |